Payers will be instrumental in determining the future commercial opportunity for biosimilars in the United States and across Europe. We conducted primary market research with surveyed MCO pharmacy and medical directors in the United States and interviewed key payer advisers in Europe to understand their perspectives on biosimilars and their expectations for biosimilar market access and reimbursement. Through our market research, we uncovered payer biosimilar pricing expectations and the likely strategies payers will adopt to drive the uptake of biosimilars in order to deliver healthcare saving. Plus we gained insight into the resulting impact on reimbursement of the reference brand and the opinion of payers on indication extrapolation, automatic substitution, and clinical data requirements.
This payer perspectives report is part of the Biosimilars Advisory Service. The Biosimilars Advisory Service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilars space. Quarterly webinars detailing major developments, analyst insight addressing key market changes, therapeutic-area-specific primary research, and forecasting modules are all included in a subscription to the Biosimilars Advisory Service. Rely on Decision Resources Group to keep you up-to-date on the biosimilars landscape and poised to maximize opportunities for your business.